An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae704 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Michael Ladurner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Metabolome, Prostate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Despite clinical suspicion of prostate cancer (PCa), 20% to 25% of patients exhibit a tumor-negative biopsy result.
Objective
This work aimed to assess the serum metabolic profile of clinically significant (cs) compared to clinically insignificant (ci) PCa or benign (Be) patients.
Methods
A total of 1078 serum samples were analyzed. Nuclear magnetic resonance (NMR) spectroscopy was used to quantify 73 metabolites; random forest was used for the model algorithm.
Results
We identified a 22-metabolite panel, which discriminated csPCa (International Society of Urological Pathology [ISUP] 2-5, n = 328) from ciPCa (ISUP 1, n = 101) and Be patients (negative biopsy, n = 649) with a higher performance when combined with the standard clinical parameters age, prostate-specific antigen (PSA), and percentage free PSA (%fPSA) (area under the curve [AUC] 0.84) than the clinical parameters alone (AUC 0.73). Our study further revealed significant dysregulations of the urea cycle and the choline pathway along with changes in tricarboxylic acid cycle, cholesterol metabolism, and a significant increase of the inflammation marker glycoprotein acetyls B in csPCa patients. In particular, ornithine and dimethylglycine were the 2 most important features to discriminate csPCa from Be + ciPCa with significantly higher ornithine and lower dimethylglycine levels in patients with csPCa (ornithine: 63.7 ± 26.5 µmol/L, dimethylglycine: 12.6 ± 6.3 µmol/L; P < .001) compared to Be + ciPCa patients (ornithine: 50.3 ± 31.6 µmol/L, dimethylglycine: 14.9 ± 7.7 µmol/L).
Conclusion
This study discovered a 22-metabolite panel to discriminate patients with csPCa from Be + ciPCa patients when combined with age, PSA, and %fPSA. It may therefore be used as a supportive biomarker to reduce the number of unnecessary biopsies and also to identify novel therapeutic targets in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
- Lifespin GmbH, 93053 Regensburg, Germany.
- Department of Internal Medicine IV Nephrology and Hypertension, Medical University of Innsbruck, 6020 Innsbruck, Austria.
ORCID-Profile: Iris E Eder
Zitieren
APA
Ladurner, M., Ameismeier, T., Klocker, H., Steiner, E., Hauffe, H., Aigner, G. P., Neuwirt, H., Böld, T., Strathmeyer, S., Heidegger, I., Drettwan, D., & Eder, I. E. (2025). An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae704
Vancouver
Ladurner M, Ameismeier T, Klocker H, Steiner E, Hauffe H, Aigner GP, et al. An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae704
BibTeX
@article{Ladurner2025,
author = {Ladurner, Michael and Ameismeier, Tobias and Klocker, Helmut and Steiner, Eberhard and Hauffe, Helga and Aigner, Gerhard P and Neuwirt, Hannes and Böld, Tina and Strathmeyer, Selina and Heidegger, Isabel and Drettwan, Diana and Eder, Iris E},
title = {An NMR-Based Metabolic Signature to Identify Clinically Significant Prostate Cancer in Patients Undergoing Biopsy},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae704}
}
EUVIMED